PKC Activation by Resveratrol Derivatives with Unsaturated Aliphatic Chain

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Pany, Satyabrata ^a   Majhi, Anjoy ^a   Das, Joydip ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3,5 DIHYDROXYSTYRYL)PHENYL OCTADECA 9,12 DIENOATE; 4 (3,5 DIHYDROXYSTYRYL)PHENYL OCTADECA 9,12,15 TRIENOATE; 4 (3,5 DIHYDROXYSTYRYL)PHENYL OLEATE; ISOENZYME; LINOLEIC ACID; LINOLENIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLEIC ACID; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C EPSILON; RESVERATROL; UNCLASSIFIED DRUG;

ABSORPTION SPECTROSCOPY; ARTICLE; BINDING SITE; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME BINDING; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE COMPLEX; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SURFACE PROPERTY;

ANIMALS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME ACTIVATION; FATTY ACIDS; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-EPSILON; SIGNAL TRANSDUCTION; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871394296     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052888     Document Type: Article

References (80)

1. Pervaiz S, (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17: 1975-1985.
2. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB, (2002) An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 50: 431-435.
3. Wu JM, Hsieh TC, (2011) Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 1215: 16-21.
4. Petrovski G, Gurusamy N, Das DK, (2011) Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 1215: 22-33.
5. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W, (2011) Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215: 89-95.
6. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB, (2011) Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215: 150-160.
7. Shukla Y, Singh R, (2011) Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci 1215: 1-8.
8. Richard T, Pawlus AD, Iglesias ML, Pedrot E, Waffo-Teguo P, et al. (2011) Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci 1215: 103-108.
9. Gusman J, Malonne H, Atassi G, (2001) A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111-1117.
10. Fremont L, (2000) Biological effects of resveratrol. Life Sci 66: 663-673.
11. Belguendouz L, Fremont L, Linard A, (1997) Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53: 1347-1355.
12. Gehm BD, McAndrews JM, Chien PY, Jameson JL, (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94: 14138-14143.
13. MacCarrone M, Lorenzon T, Guerrieri P, Agro AF, (1999) Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 265: 27-34.
14. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM, (1996) Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 246: 163-182.
15. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM, (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207-219.
16. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
17. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, et al. (2000) Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85-91.
18. Surh YJ, Hurh YJ, Kang JY, Lee E, Kong G, et al. (1999) Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett 140: 1-10.
19. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, et al. (2002) Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903.
20. Kuo PL, Chiang LC, Lin CC, (2002) Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 72: 23-34.
21. Mgbonyebi OP, Russo J, Russo IH, (1998) Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869.
22. Ratan HL, Steward WP, Gescher AJ, Mellon JK, (2002) Resveratrol-a prostate cancer chemopreventive agent? Urol Oncol 7: 223-227.
23. Hsieh TC, Wu JM, (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115.
24. Morris GZ, Williams RL, Elliott MS, Beebe SJ, (2002) Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. Prostate 52: 319-329.
25. Schwedhelm E, Maas R, Troost R, Boger RH, (2003) Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 42: 437-459.
26. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, et al. (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215: 161-169.
27. Pervaiz S, Holme AL, (2009) Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 11: 2851-2897.
28. Pirola L, Frojdo S, (2008) Resveratrol: one molecule, many targets. IUBMB Life 60: 323-332.
29. Nakashima S, (2002) Protein kinase C alpha (PKC alpha): regulation and biological function. J Biochem 132: 669-675.
30. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, et al. (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 10: 248-254.
31. Konopatskaya O, Poole AW, (2010) Protein kinase Calpha: disease regulator and therapeutic target. Trends Pharmacol Sci 31: 8-14.
32. Battaini F, Mochly-Rosen D, (2007) Happy birthday protein kinase C: past, present and future of a superfamily. Pharmacol Res 55: 461-466.
33. Koivunen J, Aaltonen V, Peltonen J, (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett 235: 1-10.
34. Griner EM, Kazanietz MG, (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7: 281-294.
35. Das Evcimen N, King GL, (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498-510.
36. Bright R, Mochly-Rosen D, (2005) The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke 36: 2781-2790.
37. Chou WH, Messing RO, (2005) Protein kinase C isozymes in stroke. Trends Cardiovasc Med 15: 47-51.
38. Sabri A, Steinberg SF, (2003) Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 251: 97-101.
39. Alkon DL, Sun MK, Nelson TJ, (2007) PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 28: 51-60.
40. Hofmann J, (2004) Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4: 125-146.
41. Newton AC, (2001) Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101: 2353-2364.
42. Nishizuka Y, (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258: 607-614.
43. Das J, Addona GH, Sandberg WS, Husain SS, Stehle T, et al. (2004) Identification of a general anesthetic binding site in the diacylglycerol-binding domain of protein kinase Cdelta. J Biol Chem 279: 37964-37972.
44. Das J, Zhou X, Miller KW, (2006) Identification of an alcohol binding site in the first cysteine-rich domain of protein kinase Cdelta. Protein Sci 15: 2107-2119.
45. Das J, Pany S, Rahman GM, Slater SJ, (2009) PKC epsilon has an alcohol-binding site in its second cysteine-rich regulatory domain. Biochem J 421: 405-413.
46. Atten MJ, Godoy-Romero E, Attar BM, Milson T, Zopel M, et al. (2005) Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 23: 111-119.
47. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, et al. (1998) Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273: 21875-21882.
48. Stewart JR, O'Brian CA, (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 22: 107-117.
49. Stewart JR, Ward NE, Ioannides CG, O'Brian CA, (1999) Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38: 13244-13251.
50. Slater SJ, Seiz JL, Cook AC, Stagliano BA, Buzas CJ, (2003) Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 1637: 59-69.
51. Ferrero ME, Bertelli AE, Fulgenzi A, Pellegatta F, Corsi MM, et al. (1998) Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 68: 1208-1214.
52. Chen CK, Pace-Asciak CR, (1996) Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 27: 363-366.
53. Kimura Y, Okuda H, Arichi S, (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834: 275-278.
54. Das J, Pany S, Majhi A, (2011) Chemical modifications of resveratrol for improved protein kinase C alpha activity. Bioorg Med Chem 19: 5321-5333.
55. Babich H, Reisbaum AG, Zuckerbraun HL, (2000) In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett 114: 143-153.
56. Shirai Y, Kashiwagi K, Yagi K, Sakai N, Saito N, (1998) Distinct effects of fatty acids on translocation of gamma- and epsilon-subspecies of protein kinase C. J Cell Biol. 143: 511-521.
57. Yang YM, Wang XX, Chen JZ, Wang SJ, Hu H, et al. (2008) Resveratrol attenuates adenosine diphosphate-induced platelet activation by reducing protein kinase C activity. Am J Chin Med 36: 603-613.
58. Endo Y, Yokoyama A, (2000) Role of the hydrophobic moiety of tumor promoters. Synthesis and activity of 2-alkylated benzolactams. Bioorg Med Chem Lett 10: 63-66.
59. Wooten MW, Wrenn RW, (1988) Linoleic acid is a potent activator of protein kinase C type III-alpha isoform in pancreatic acinar cells; its role in amylase secretion. Biochem Biophys Res Commun 153: 67-73.
60. Shinomura T, Asaoka Y, Oka M, Yoshida K, Nishizuka Y, (1991) Synergistic action of diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible implications. Proc Natl Acad Sci U S A 88: 5149-5153.
61. Murakami K, Chan SY, Routtenberg A, (1986) Protein kinase C activation by cis-fatty acid in the absence of Ca2+ and phospholipids. J Biol Chem 261: 15424-15429.
62. Pi Y, Walker JW, (2000) Diacylglycerol and fatty acids synergistically increase cardiomyocyte contraction via activation of PKC. Am J Physiol Heart Circ Physiol 279: H26-34.
63. Yaguchi T, Yamamoto S, Nagata T, Kanno T, Tanaka A, et al. (2005) Effects of cis-unsaturated free fatty acids on PKC-epsilon activation and nicotinic ACh receptor responses. Brain Res Mol Brain Res 133: 320-324.
64. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB, (2001) Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry 6: 246-248.
65. Prades J, Funari SS, Escriba PV, Barcelo F, (2003) Effects of unsaturated fatty acids and triacylglycerols on phosphatidylethanolamine membrane structure. J Lipid Res 44: 1720-1727.
66. Rawicz W, Olbrich KC, McIntosh T, Needham D, Evans E, (2000) Effect of chain length and unsaturation on elasticity of lipid bilayers. Biophys J 79: 328-339.
67. Yamatsugu K, Motoki R, Kanai M, Shibasaki M, (2006) Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton. Chem Asian J 1: 314-321.
68. Wada R, Suto Y, Kanai M, Shibasaki M, (2002) Dramatic switching of protein kinase C agonist/antagonist activity by modifying the 12-ester side chain of phorbol esters. J Am Chem Soc 124: 10658-10659.
69. Sodeoka M, Arai MA, Adachi K, Uotsu K, Shibasaki M, (1998) Rational Design, Synthesis, and Evaluation of a New Type of PKC Inhibitor. J Am Chem Soc 120: 457-458.
70. Irie K, Oie K, Nakahara A, Yanai Y, Ohigashi H, et al. (1998) Molecular basis for Protein Kinase C isozyme-selective binding: the systhesis, folding, and phorbol ester binding of the cysteine-rich domains of all Protein Kinase C isozymes. J Am Chem Soc 120: 9159-9167.
71. Ananthanarayanan B, Stahelin RV, Digman MA, Cho W, (2003) Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains. J Biol Chem 278: 46886-46894.
72. Stahelin RV, Digman MA, Medkova M, Ananthanarayanan B, Melowic HR, et al. (2005) Diacylglycerol-induced membrane targeting and activation of protein kinase Cepsilon: mechanistic differences between protein kinases Cdelta and Cepsilon. J Biol Chem 280: 19784-19793.
73. Geczy T, Peach ML, El Kazzouli S, Sigano DM, Kang JH, et al. (2012) Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester. J Biol Chem 287: 13137-13158.
74. Aires V, Hichami A, Filomenko R, Ple A, Rebe C, et al. (2007) Docosahexaenoic acid induces increases in [Ca2+]i via inositol 1,4,5-triphosphate production and activates protein kinase C gamma and-delta via phosphatidylserine binding site: implication in apoptosis in U937 cells. Mol Pharmacol 72: 1545-1556.
75. Kanno T, Yamamoto H, Yaguchi T, Hi R, Mukasa T, et al. (2006) The linoleic acid derivative DCP-LA selectively activates PKC-epsilon, possibly binding to the phosphatidylserine binding site. J Lipid Res 47: 1146-1156.
76. Nelson TJ, Cui C, Luo Y, Alkon DL, (2009) Reduction of beta-amyloid levels by novel protein kinase C(epsilon) activators. J Biol Chem 284: 34514-34521.
77. Banci L, Cavallaro G, Kheifets V, Mochly-Rosen D, (2002) Molecular dynamics characterization of the C2 domain of protein kinase Cbeta. J Biol Chem 277: 12988-12997.
78. Liu Q, Molkentin JD, (2011) Protein kinase Calpha as a heart failure therapeutic target. J Mol Cell Cardiol 51: 474-478.
79. Teicher BA, (2006) Protein kinase C as a therapeutic target. Clin Cancer Res 12: 5336-5345.
80. Majhi A, Rahman GM, Panchal S, Das J, (2010) Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C. Bioorg Med Chem. 18: 1591-1598.